Condition: Retinopathy of Prematurity · Sponsor: Asociación para Evitar la Ceguera en México
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
This description comes directly from the study's public registry record.
Hugo Quiroz-Mercado, MD · 525510841400 · retinamex@yahoo.com
Maria A Martínez-Castellanos, MD · 525510841400 · retinamex@yahoo.com
Always discuss trial participation with your own doctor first.
| Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes" | Mexico City, Mexico DF, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00346814